HI
JAZZ icon

HBK Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

HBK Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,200
Closed -$1.59M – 1069
2017
Q2 		$1.59M Buy
+10,200
New +$1.56M 0.01% 466

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HBK Investments's JAZZ Position: Q1 2019 in Review

HBK Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 61,900 shares — an estimated $7.67M sold.

HBK Investments first reported a position in JAZZ in Q2 2013 and held it in 17 quarters. The position peaked at $16.9M in Q1 2014. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • HBK Investments reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • HBK Investments sold 61,900 Jazz Pharmaceuticals shares in Q1 2019, an estimated $7.67M.
  • HBK Investments first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • HBK Investments's Jazz Pharmaceuticals position peaked at $16.9M in Q1 2014.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on HBK Investments's 13F filing for Q1 2019, filed 15 May 2019.